Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 3:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 309 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluzone inactivated influenza vaccine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

NCT00382980
View directory record Official record
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Vero cell based whole virus influenza A/H5N1, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
5
States / cities
Stanford, California • Torrance, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Influenza Vaccine in Pregnant Women

NCT00905125
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®, Fluarix®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
9
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

NCT01498718
View directory record Official record
Conditions
Influenza
Interventions
DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 2 Interventional Results available

H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

NCT00992433
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza H1N1 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

NCT05874713
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
9
States / cities
Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus

NCT01044095
View directory record Official record
Conditions
Influenza
Interventions
FluMist® live, attenuated, intranasal seasonal influenza vaccine, Fluzone® inactivated influenza virus vaccine
Biological
Lead sponsor
Armed Forces Research Institute of Medical Sciences, Thailand
Government
Eligibility
18 Years to 49 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

NCT01246999
View directory record Official record
Conditions
Influenza
Interventions
Live attenuated Influenza vaccine, Trivalent Influenza Vaccine, TIV followed by LAIV, LAIV followed by TIV
Biological
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 9 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

NCT00772109
View directory record Official record
Conditions
Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions
Influenza Virus Vaccine USP Trivalent Types A and B
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
4,292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
46
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 4 Interventional Results available

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

NCT04667117
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Quadrivalent influenza vaccine, Ofatumumab, iDMT
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Phoenix, Arizona • Hollywood, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

NCT02545543
View directory record Official record
Conditions
Influenza, Human
Interventions
Seqirus QIV, Comparator QIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
5 Years to 17 Years
Enrollment
2,278 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
32
States / cities
Huntsville, Alabama • Madera, California • Ontario, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695117
View directory record Official record
Conditions
COVID-19 Immunization, Influenza Immunization
Interventions
IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1), IIV-HD + rC19 (dose 2), IIV-HD + rC19 (dose 3), IIV-HD + rC19 (dose 4), Placebo (0.9% NaCl)
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.

NCT01691339
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Boca Raton, Florida • South Miami, Florida • Council Bluffs, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Oct 14, 2026, 3:19 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

NCT05108818
View directory record Official record
Conditions
Influenza, Human
Interventions
Seasonal influenza vaccine
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 14, 2026, 3:19 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Influenza Vaccine as a Novel Experimental Model of the Behavioral Immune Response in Depression

NCT03756246
View directory record Official record
Conditions
Depression, Healthy
Interventions
Influenza Vaccine
Biological
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 14, 2026, 3:19 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children

NCT01097941
View directory record Official record
Conditions
2009 H1N1 Influenza
Interventions
Live Attenuated H1N1 Influenza Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine, Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live
Biological
Lead sponsor
University of Rochester
Other
Eligibility
4 Years to 9 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 14, 2026, 3:19 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

NCT01924169
View directory record Official record
Conditions
Hematologic Disorder
Interventions
Lenalidomide, Influenza Vaccine, Pneumovax Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

NCT00782431
View directory record Official record
Conditions
Influenza
Interventions
Vero cell derived, trivalent, seasonal influenza vaccine, Licensed egg-derived, trivalent seasonal influenza vaccine
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
50 Years and older
Enrollment
3,208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
30
States / cities
Mobile, Alabama • Tucson, Arizona • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 14, 2026, 3:19 AM EDT
Completed No phase listed Observational Results available

FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging

NCT01467934
View directory record Official record
Conditions
Fever
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
6 Months to 23 Months
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old

NCT01992107
View directory record Official record
Conditions
Influenza
Interventions
QIVc, TIV1c, TIV2c
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
4 Years to 18 Years
Enrollment
2,333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
88
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 14, 2026, 3:19 AM EDT
Recruiting Phase 2 Interventional

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

NCT05947071
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Stanford, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

NCT02553343
View directory record Official record
Conditions
Influenza
Interventions
High-dose quadrivalent influenza virus vaccine, High-dose influenza virus vaccine, High-dose trivalent inactivated influenza vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
792 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
9
States / cities
Milford, Connecticut • Coral Gables, Florida • Wichita, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

NCT00264576
View directory record Official record
Conditions
Influenza Disease; Flu
Interventions
Influenza Virus Vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years to 49 Years
Enrollment
613 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
4
States / cities
Bardstown, Kentucky • Pittsburgh, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Young Adult Influenza Vaccine Immunogenicity Substudy

NCT00170508
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 14, 2026, 3:19 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A/H5N1/LT Dose Ranging Study

NCT00908687
View directory record Official record
Conditions
Pandemic Influenza
Interventions
A/H5N1, LT Adjuvant Patch
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
6
States / cities
Anaheim, California • Vallejo, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Oct 14, 2026, 3:19 AM EDT